Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study details a 31-year-old woman diagnosed with secondary syphilis that presented with chronic headaches and hair loss, ultimately attributed to neurosyphilis and alopecia syphilitica.

This study found that combining platelet-rich plasma with topical minoxidil improved hair density and patient satisfaction in androgenetic alopecia patients more than minoxidil alone, with no serious adverse events reported.

This review discusses the use of platelet-rich plasma as a treatment for androgenetic alopecia and highlights the need for standardized protocols, reporting no new clinical results.

This study found that 363 genes were differentially expressed in alopecia areata skin compared to non-lesional skin, suggesting T-cell mediated immune responses and distinct gene profiles related to the disease's stage.

Finasteride is effective for hair loss and may help prevent prostate cancer without increasing high-grade cancer risk.

This study found that a herbal shampoo and solution were more effective than placebo in reducing hair loss and improving hair growth in participants with androgenetic alopecia and telogen effluvium.

This study suggests that greater sensitivity to androgens, as indicated by higher than grade 2 androgenic alopecia, may reduce the risk of schizophrenia by 8.62 times.

This study observed that among men aged 18 to 35 with early onset androgenetic alopecia, those with severe grades and metabolic syndrome may face increased cardiovascular risks, highlighting the importance of screening and monitoring.

This study suggests that the floral secretions of Brasiliorchis schunkeana may attract Diptera as potential pollinators, but field observations are needed to confirm this pollination syndrome.

In this study, injecting two different concentrations of botulinum toxin A was found to be safe and effective for treating androgenetic alopecia in Egyptian men and women, with improvements in hair grade and vellus hair density observed over six months.

In this study, topical tofacitinib significantly increased hair regrowth in mice compared to minoxidil or vehicle, potentially due to elevated VEGF levels and reduced inflammation.

This study found an association between vertex baldness and prostate cancer, especially for high-grade tumors in men aged 60-69, suggesting a possible shared androgen pathway.

This study found that non-ablative Er:YAG laser treatment, alone or combined with other therapies, effectively improved hair quality and reduced AGA grade in patients, with high satisfaction reported and no adverse reactions.

In this study, women with PCOS exhibited a significantly elevated low-grade inflammatory profile through salivary cytokines, with IL-1β and TNF-α demonstrating strong potential as non-invasive diagnostic markers, alongside traditional androgen measures like FAI.

In this study, tofacitinib showed significant efficacy in treating alopecia totalis and universalis over a 6-month period, with notable hair regrowth outcomes, while younger age of onset and shorter treatment duration were linked to less effectiveness.

In this study, PRP therapy did not show significant effectiveness in treating androgenetic alopecia in patients over a 6-month period, with 45% of participants reporting no improvement in hair growth, although adverse effects were minimal and non-serious.

Microneedling with PRP and minoxidil (5%) improves hair growth more than minoxidil (5%) alone.

This article discusses androgenetic alopecia and reports no new clinical results.

This study found that among men with male pattern hair loss, taking 1mg of finasteride daily for two years slowed hair loss progression and increased hair growth.

This study found that dutasteride mesotherapy increased the diameter of existing hair in five Mexican men with androgenetic alopecia, without reported side effects.

This review summarizes current and emerging treatments for common hair loss conditions, highlighting good evidence for androgenetic alopecia but noting the lack of long-term data for alopecia areata and cicatricial alopecias.

In this study, permanent alopecia after haematopoietic stem cell transplantation was found in 16% of patients and was significantly associated with conditioning regimens involving busulphan.

In this clinical trial, supplementation with Lambdapil® Anti Hair Loss capsules for 6 months significantly improved hair resistance and volume in women and increased the anagen/telogen hair ratio in men, indicating enhanced hair growth compared to the placebo group.

In this study, intradermal injections of QR678 were found to significantly reduce hair fall in men with androgenetic alopecia over 6 months, with superior improvements in hair density and thickness compared to PRP.

In this study, a photographic scale and questionnaire revealed that extensive central scalp hair loss was observed in 5.6% of African American women, with an association to a history of tinea capitis.

This study found that 58% of men aged 30-50 had androgenic alopecia, with disease severity increasing with age and many being candidates for medical treatment or hair transplantation.

This study evaluated the effect of 2% ketoconazole lotion for androgenetic alopecia, but the results regarding its effectiveness on clinical appearance remained unclear.

This study found that males with androgenetic alopecia had a higher risk of coronary artery disease, with significant differences in several lipid and blood pressure markers compared to controls.

In this study, five out of six patients treated with vemurafenib for metastatic melanoma experienced hair loss, which improved after topical steroid treatment.

This study found that 5% topical minoxidil was moderately more effective at increasing hair regrowth than 10% minoxidil and placebo in men with androgenetic alopecia.